Shelbi Jim On, MD
Dermatology · Honolulu, HINPI 1184923765
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,625, more than ten times the $15 reported in 2019.
Across 365 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$979
- Regeneron Healthcare Solutions, Inc.$910
- Sanofi$787
- Amgen$694
- LEO Pharma Inc.$545
- plus $3K from 20 others
Across 1 payment — averaging $824.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$824
What the payments were for
- Food & beverage$8,70398%
- Education$1382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 84 | $1,933 |
| Lilly USA, LLC | 37 | $979 |
| Regeneron Healthcare Solutions, Inc. | 27 | $910 |
| Sanofi | 23 | $787 |
| Amgen | 29 | $694 |
| LEO Pharma Inc. | 27 | $545 |
| Incyte Corporation | 15 | $421 |
| Galderma Laboratories, L.p. | 20 | $363 |
| E.r. Squibb & Sons, L.L.C. | 11 | $304 |
| Sun Pharmaceutical Industries Inc. | 12 | $276 |
| UCB, Inc. | 11 | $253 |
| Genentech USA, Inc. | 15 | $252 |
| Novartis | 12 | $235 |
| Pfizer | 11 | $203 |
| Organon | 8 | $189 |
| Merz North America, Inc. | 5 | $97 |
| Johnson & Johnson | 3 | $94 |
| Prugen, Inc. Pharmaceuticals | 1 | $75 |
| Arcutis Biotherapeutics, Inc. | 4 | $59 |
| Biofrontera Inc. | 3 | $50 |
| Solta Medical, A Division Of Bausch Health US, LLC | 2 | $35 |
| Revance Therapeutics, Inc. | 1 | $28 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $20 |
| Almirall LLC | 1 | $16 |
| Dermavant Sciences, Inc. | 1 | $14 |
| VYNE Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,842 in reported general payments places this provider in the 70th percentile of 67 dermatology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $67,521 |
| OtezlaApremilast | 12 | $58,387 |
| Tacrolimus | 23 | $3,155 |
| Clobetasol Propionate | 63 | $2,817 |
| Calcipotriene | 16 | $2,297 |
| Halobetasol Propionate | 49 | $2,134 |
| Fluorouracil | 41 | $1,831 |
| Triamcinolone Acetonide | 54 | $1,165 |
| Ketoconazole | 71 | $1,137 |
| Tretinoin | 13 | $1,059 |
| Fluocinonide | 21 | $945 |
| Mupirocin | 113 | $893 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 11 | $725 |
| Gentamicin Sulfate | 16 | $669 |
| Ammonium Lactate | 25 | $651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $694 | $58,38712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 67 dermatology providers in Hawaii.
Other dermatology in Honolulu
- Sarah HowellHonolulu$653K
- Douglas JohnsonHonolulu$568K
- Ryan SatoHonolulu$226K
- Greg SakamotoHonolulu$20K
- Kory KitagawaHonolulu$18K
- Kevin DawsonHonolulu$16K
- Dylan LeeHonolulu$15K
- Sarah GrekinHonolulu$13K
- Gregory HerbichHonolulu$12K
- Stella MatsudaHonolulu$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.